Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04360837
Recruitment Status : Recruiting
First Posted : April 24, 2020
Last Update Posted : May 21, 2020
Sponsor:
Collaborators:
Furtwangen University
BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS
Information provided by (Responsible Party):
András Lovas, Szeged University

Brief Summary:

COVID-19 originated from Severe Acut Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection leads to critical condition due to hypoxemic respiratory failure with the background of viral pneumonia. Both alevolar recruitment and the subsequent optimal positive end-expiratory pressure (PEEP) adjustment has a pivotal role in the elimination of atelectasis developed by inflammation in the lung parenchyma The gold standard of the follow up of recruitment manoeuvre is the chest computed tomography (CT) examination. However, reduction of intrahospital transport and the exposure with healthcare workers are recommended because of the extremely virulent pathogen spreading easily by droplet infection. In this case bedside investigations have an utmost importance in the management of hygiene regulations.

Electric impedance tomography (EIT) is a non-invasive, radiation free functional imaging technique easily applicable at the bedside.


Condition or disease Intervention/treatment Phase
COVID-19 Virus; Pneumonia Atelectasis Procedure: alveolar recruitment Not Applicable

Detailed Description:

COVID-19 originated from Severe Acut Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection leads to critical condition in 5% of the cases due to hypoxemic respiratory failure with the background of viral pneumonia. 90% of these patients require invasive mechanical ventilation on critical care units. Both alevolar recruitment and the subsequent optimal positive end-expiratory pressure (PEEP) adjustment has a pivotal role in the eliminitaion of atelectasis developed by inflammation in the lung parenchyma.

The gold standard of the follow up of recruitment manoeuvre is the chest computed tomography (CT) examination. However, reduction of intrahospital transport and the exposure with healthcare workers are recommended because of the extremely virulent pathogen spreading easily by droplet infection. In this case bedside investigations have an utmost importance in the management of hygiene regulations.

Electric impedance tomography (EIT) is a non-invasive, radiation free functional imaging technique easily applicable at the bedside. With the help of EIT, intrathoracic impedance changes, resulting from air and blood volume variations, can be determined by circumferentially attached surface electrodes around the thorax, applying small alternating currents and measuring differences in surface potentials. The calculated difference in potential is utilised to reconstruct impedance images what is employed to assess ventilation and perfusion distribution. Several local and global variances can be estimated just like the ratio fo atelectatic/overdistended alveoli, the ratio of aeration in the anterior/posterior regions, the inhomogeneity of aeration or regional compliance.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT)
Actual Study Start Date : May 6, 2020
Estimated Primary Completion Date : June 1, 2021
Estimated Study Completion Date : June 1, 2021

Arm Intervention/treatment
Experimental: PEEP incremental-decremental alveolar recruitment
  1. installing EIT belt over the chest at the level of the 5th intercostal space and adjustment of the default recruitment settings in pressure control ventilation mode: pressure control 15 cmH20, PEEP 10 cmH2O, fraction of inspired oxygen (FiO2) and respiratory rate according to the discretion of the attending physician, recording basal parameters
  2. implementation of recruitment:

    • increment phase: increasing PEEP by 3 cmH2O in every two minutes from 10 cmH2O until top of PEEP 25 cmH2O
    • decrement phase: decreasing PEEP by 3 cmH20 in every two minutes from 25 cmH20 until the basal PEEP 10 cmH20
    • end inspiratory hold manoeuvre at every PEEP level
  3. recording closing parameters

Repeating the above detailed intervention once daily as long as the patient is controlled ventilation.

Procedure: alveolar recruitment
incremental and decremental positive end-expiratory pressure alveolar recruitment




Primary Outcome Measures :
  1. Changes in lung compliance [ Time Frame: 20 minutes ]
    Estimation of change in compliance (ml/cmH2O) from the beginning to end of of the incremental/decremental PEEP alveolar recruitment.

  2. Change in global impedance [ Time Frame: 20 minutes ]
    Estimation of change in global impedance (%) from the beginning to end of of the incremental/decremental PEEP alveolar recruitment.

  3. Change in recruitability [ Time Frame: 7 days ]
    Estimation of change in global impedance (%) on a daily manner.


Secondary Outcome Measures :
  1. Gas exchange [ Time Frame: 20 minutes and 7 days ]
    Change in arterial partial pressure of oxygen (PaO2) (mmHg) following recruitment

  2. Plateau pressure [ Time Frame: 20 minutes and 7 days ]
    Change in plateau pressure (cmH2O) following recruitment

  3. End expiratory lung impedance (EELI) [ Time Frame: 20 minutes and 7 days ]
    Change in end expiratory lung impedance (%)

  4. Antero-to-posterior ventilation ratio [ Time Frame: 20 minutes and 7 days ]
    Change in antero-to-posterior ventilation ratio (%) following intervention

  5. Center of ventilation [ Time Frame: 20 minutes and 7 days ]
    Change in center of ventilation (%) following intervention

  6. Global inhomogeneity index [ Time Frame: 20 minutes and 7 days ]
    Change in global inhomogeneity index (%) following intervention



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • SARS-CoV-2 positivity confirmed by polymerase chain reaction
  • orotracheally intubated patients
  • pressure control ventilation mode
  • sedation level of minimum -4 on the Richmond Agitation Sedation Scale (RASS)

Exclusion Criteria:

  • age under 18
  • pregnancy
  • pulmonectomy, lung resection in the past medical history
  • clinically end stage chronic obstructive pulmonary disease
  • sever hemodynamic instability (vasopressor refractory shock)
  • sever bullous emphysema and/or spontaneous pneumothorax in the past medical history chest drainage in situ due to pneumothorax and/or bronchopleural fistula

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04360837


Contacts
Layout table for location contacts
Contact: András Lovas, MD PhD 003662545168 lovas.andras@med.u-szeged.hu

Locations
Layout table for location information
Hungary
University of Szeged Recruiting
Szeged, Hungary, 6725
Contact: András Lovas, MD         
Sponsors and Collaborators
Szeged University
Furtwangen University
BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS
Investigators
Layout table for investigator information
Principal Investigator: András Lovas, MD PhD SZTE AITI
Publications of Results:
Other Publications:
Layout table for additonal information
Responsible Party: András Lovas, consultatnt in critical care and anaesthesiology, Szeged University
ClinicalTrials.gov Identifier: NCT04360837    
Other Study ID Numbers: COVID-19EIT
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: May 21, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia, Viral
Pneumonia
Pulmonary Atelectasis
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases